Abstract
Our results provide further evidence for the hypothesis that the mouse vas deferens contains cannabinoid CB 1 receptors. Thus we found that in the presence of forskolin, the cannabinoid receptor agonist, CP 55,940 ((−)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-l-ol) produced a concentration related inhibition of cyclic AMP production by the vas deferens (EC 50 = 6.0 nM). At 100 nM, SR141716A ( N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1 H-pyrazole-3-carboxamide hydrochloride) attenuated this effect of CP 55,940, producing a parallel rightward shift in its log concentration-response curve ( K d = 4.3 nM). We also found that cyclic AMP production was inhibited by (−)-11-hydroxy-1′,1′-dimethylheptyl- Δ 8-tetrahydrocannabinol but not by the (+) enantiomer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
